{"commentary":{"count":38,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"podcast":4,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05863195\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05863195","nct_id":"NCT05863195","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05863195. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single SPECT/CT on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.","label":"Arm A (HAI, floxuridine, standard chemotherapy)","type":"EXPERIMENTAL"},{"description":"Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI IV, FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine PO in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.","label":"Arm B (standard chemotherapy)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":{"count":408,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bevacizumab","type":"BIOLOGICAL"},{"name":"Capecitabine","type":"DRUG"},{"name":"Cetuximab","type":"BIOLOGICAL"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Floxuridine","type":"DRUG"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Implantation","type":"PROCEDURE"},{"name":"Intrahepatic Infusion Procedure","type":"PROCEDURE"},{"name":"Irinotecan","type":"DRUG"},{"name":"Leucovorin","type":"DRUG"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Panitumumab","type":"BIOLOGICAL"},{"name":"Single Photon Emission Computed Tomography","type":"PROCEDURE"}],"last_update":"2026-09-24","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"From randomization to death from any cause, assessed up to 5 years"}],"references":[],"start_date":{"date":"2024-04-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","url":"https://clinicaltrials.gov/study/NCT05863195"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05863195"}